Bioavailability of dihydroergotamine.

Treatment of orthostatic hypotension with dihydroergotamine.

Intravenous dihydroergotamine for inpatient management of refractory primary headaches.

OBJECTIVE To determine dosing and side effects of dihydroergotamine as they affect outcomes in primary headache disorders. METHODS We audited our use of dihydroergotamine for inpatient management of disabling primary headache, focusing on the commonly treated problems. RESULTS Of patients interviewed, 114 had chronic migraine, 38 had cluster headache, and 11 had new daily persistent headach...

Aprepitant for the management of nausea with inpatient IV dihydroergotamine

OBJECTIVE To assess the efficacy and tolerability of oral aprepitant, a substance P/neurokinin A receptor antagonist, in controlling nausea associated with IV dihydroergotamine (DHE) administered for medically refractory migrainous headache in patients not responding to standard antiemetics or with a history of uncontrolled nausea with DHE. METHODS This was a retrospective chart review of pro...

Haemodynamic effects of three doses of dihydroergotamine during spinal anaesthesia.

We performed a randomized study comparing the haemodynamic effects of three doses of the vasopressor dihydroergotamine (DHE) (5, 10 and 15 microg x kg(-1)) in 30 ASA 1 and 2 patients, aged 53-87 yr, undergoing spinal anaesthesia. Non-invasive systolic arterial pressure (SAP), heart rate and central venous pressure (CVP) were recorded continuously for 25 min. Intravenous fluids were withheld dur...

Repetitive intravenous dihydroergotamine as therapy for intractable migraine.

For patients with chronic intractable headache, we compared a new treatment and a traditional one. Fifty-five patients (36 dependent on ergotamine, analgesics, diazepam, or corticosteroids) were given IV dihydroergotamine (DHE) and metoclopramide every 8 hours. Fifty-four age- and sex-matched patients (38 drug-dependent) were given diazepam intravenously every 8 hours. Forty-nine of the 55 DHE-...